Last updated: 2026-09-05 12:12:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MBX Biosciences, Inc. (MBX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $61,70, with a market capitalization of $2,96B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9,63 to $72,64. This page covers its latest market performance, valuation, price trends and company information.
$2,96B | |
$61,00 | |
$72,64 | |
$4,81 | |
$61,42 | |
229,38K | |
741,69K | |
-- | |
$72,64 | |
$9,63 | |
-- | |
-- |
MBX Biosciences, Inc. (MBX) last closed at $61,42 as of 2026-09-04 23:31:00, unchanged from the previous close of $61,42.
During the latest regular trading session, MBX traded between $4,81 and $72,64, with a volume of 229,38K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, MBX Biosciences, Inc. (MBX) moved from $66,39 to $61,70, representing a decline of 7,07% ($4,69).
The stock traded between $58,80 and $66,90 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 346,04 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82,6%
MBX is currently trading at $61,70, placing it 82,6% of the way from its 52-week low of $9,63 to its 52-week high of $72,64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 63 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MBX Biosciences, Inc. (MBX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.